ALVOAlvotech
Is the business good?
Profits without cash flow. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Reports an operating profit but operating cash flow is negative, a red flag.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is ALVO?
Alvotech earns 7.3% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 1.7 points below what the capital costs: growth destroys value
- Operating margin
- 13%
Operating margin · Drug Manufacturers - Specialty & Generic median 9.5% · fiscal year to FY2025
- Cash conversion
- −0.81×
Cash conversion · the operating profit has not turned into cash yet
- Share count, year on year
- +8.7%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2020 | −206% |
| FY2021 | −640% |
| FY2022 | −417% |
| FY2023 | −388% |
| FY2024 | 14% |
| FY2025 | 13% |
Details›
- Gross marginfiscal year to FY2025
- 60%
- Operating marginfiscal year to FY2025
- 13%
- Net marginfiscal year to FY2025
- 4.8%
- Free cash flow margin
- −20%
- R&D as % of revenue
- 31%
- Revenue, trailing twelve months
- $586M
- Free cash flow, trailing twelve months
- −$115M
- Net income, trailing twelve months
- $28M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 7.3%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #27 of 39 by RyuScore